The Department of Pharmaceuticals (DoP) has barred drug
from withdrawing its Xience Alpine coronary stent from the market. The government move comes following its directive to companies
to maintain an uninterrupted supply of stents.
order effectively sets aside the National Pharmaceutical Pricing Authority's (NPPA) decision to allow Abbott
to withdraw the Xience Alpine stent for commercial reasons. In an order earlier this week the NPPA
to withdraw the stent over one-year period after issuing a public notice for the same.
In its office memorandum on Friday, DoP
said that it had on Wednesday invoked powers under section 3 of the Drug
Order of 2013 and directed companies
manufacturing coronary stents
to maintain uninterrupted supply for three months from the date of notification.
said that its Thursday's order supersedes the NPPA
decision earlier this week and makes it null and void. Abbott
has also been directed to submit a weekly report on coronary stents
produced and distributed and also submit a weekly production plan to the NPPA
Controller General of India.
did not immediately comment on the DoP
Last month Abbott
globally withdrew its bioresorbable stent Absorb citing commercial reasons.